JimmyHwangMD

Oncology • Charlotte, NC

Chief, GI Medical Oncology; Director Hematology/Oncology Fellowship; Levine Cancer Institute, Atrium Health

Join to view full profile

Dr. Hwang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hwang's full profile

Already have an account?

Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204
Phone+1 980-442-2000

Fax+1 980-442-6141

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1998 - 2001
UPMC Medical EducationResidency, Internal Medicine, 1995 - 1998
University of Pittsburgh School of MedicineClass of 1995

Certifications & Licensure

NC State Medical License 2013 - 2025
DC State Medical License 2001 - 2014
MD State Medical License 2010 - 2014
VA State Medical License 2001 - 2010
PA State Medical License 1996 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Jan 01
Completed
Phase 1
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2015 Jul 07
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01
Completed
Phase 1, Phase 2
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Role ofgene expression in colorectal cancer: a comprehensive molecular profiling study.
Hiroyuki Arai, Nishant Gandhi, Francesca Battaglin, Jingyuan Wang, Sandra Algaze
Journal for Immunotherapy of Cancer. 2024-11-05
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.
Jingyuan Wang, Joanne Xiu, Francesca Battaglin, Hiroyuki Arai, Shivani Soni
NPJ Precision Oncology. 2024-09-30
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20

Abstracts/Posters

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Jimmy Hwang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Authored Content

ASCO GI: Updates in Rectal Cancer and the FIGHT StudyJanuary 2021

Press Mentions

Early Discovery of Liver Disease Improves Chances to Cure Liver CancerOctober 21st, 2021
ASCO GI: Updates in Rectal Cancer and the FIGHT StudyJanuary 25th, 2021
I’ll Never Stop FightingAugust 22nd, 2019
Join now to see all